SubHero Banner
Text

Humira® (adalimumab) – Expanded indication

October 16, 2018 - The FDA approved AbbVie’s Humira (adalimumab) for the treatment of moderate to severe hidradenitis suppurativa (HS) in patients ≥ 12 years of age.

Download PDF